Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 6/2006

01.06.2006 | Original Article

Inhibition of cytokinesis and akt phosphorylation by chaetoglobosin K in ras-transformed epithelial cells

verfasst von: Diane F. Matesic, Kimberly N. Villio, Stacey L. Folse, Erin L. Garcia, Stephen J. Cutler, Horace G. Cutler

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2006

Einloggen, um Zugang zu erhalten

Abstract

Purpose: Chaetoglobosin K (ChK), a bioactive natural product previously shown to have anti-tumor promoting activity in glial cells and growth inhibitory effects in ras-transformed fibroblasts, inhibited anchorage-dependent and anchorage-independent growth in ras-transformed liver epithelial cells. The purpose of this study was to identify cellular targets of ChK that mediate its anti-tumor effects. Methods: Anchorage-independent cell growth assays, using soft agar-coated dishes, and anchorage-dependent growth assays were performed on transformed WB- ras1 cells. Phase/contrast and fluorescent microscopy were used to visualize cell morphological changes and DAPI-stained nuclei. Analyses of p21 Ras membrane versus cytosolic forms, p44/42 mitogen-activated protein kinase (MAPK) phosphorylation, Akt kinase phosphorylation and connexin 43 phosphorylation were performed by Western blotting. Gap junction-mediated cellular communication was measured by fluorescent dye transfer. Results: Treatment of WB- ras1 cells with a non-cytotoxic dose of ChK inhibited both anchorage-dependent and anchorage-independent growth. Inhibited cells were generally larger and less spindle-shaped in morphology than vehicle-treated cells, many of which were multinucleate. Removal of ChK induced cytokinesis and a return to predominantly single-nucleate cells, suggesting that ChK inhibits cytokinesis. The proportion of membrane-associated versus cytosolic forms of p21 Ras was unchanged by ChK treatment, suggesting that ChK does not act as a farnesylation inhibitor. ChK treatment decreased the level of phosphorylation of Akt kinase, a key signal transducer of the Phosphatidylinositol 3-kinase pathway. In contrast, ChK had no effect on phosphorylation of p44/42 MAPK, which mediates the MAPK/ERK Ras effector pathway. Phosphorylation of the gap junction protein, connexin 43, shown previously to increase following treatment with other anti-Ras compounds, was also not altered by ChK, which correlated with its lack of effect on gap junction-mediated cellular communication. Conclusions: Our results demonstrate that ChK inhibits Akt kinase phosphorylation and cytokinesis in ras-transformed cells, which likely contribute to its ability to inhibit tumorigenic growth.
Literatur
1.
Zurück zum Zitat Adjei AA (2001) Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93:1062–1074CrossRefPubMed Adjei AA (2001) Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93:1062–1074CrossRefPubMed
3.
Zurück zum Zitat Malumbres M, Barbacid M (2003) RAS oncogenes: the first 30 years. Nat Rev Cancer 3:7–13CrossRef Malumbres M, Barbacid M (2003) RAS oncogenes: the first 30 years. Nat Rev Cancer 3:7–13CrossRef
4.
Zurück zum Zitat Hamad NM, Elconin JH, Karnoub AE, Bai W, Rich JN, Abraham RT, Der CJ, Counter CM (2002) Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev 16:2045–2057CrossRefPubMed Hamad NM, Elconin JH, Karnoub AE, Bai W, Rich JN, Abraham RT, Der CJ, Counter CM (2002) Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev 16:2045–2057CrossRefPubMed
5.
Zurück zum Zitat Cesen-Cummings K, Warner KA, Ruch RJ (1998) Role of protein kinase C in the deficient gap junctional intercellular communication of K-ras-transformed murine lung epithelial cells. Anticancer Res 18:4343–4346PubMed Cesen-Cummings K, Warner KA, Ruch RJ (1998) Role of protein kinase C in the deficient gap junctional intercellular communication of K-ras-transformed murine lung epithelial cells. Anticancer Res 18:4343–4346PubMed
6.
Zurück zum Zitat Kolch W (2000) Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 351:289–305CrossRefPubMed Kolch W (2000) Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 351:289–305CrossRefPubMed
7.
Zurück zum Zitat Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, Waterfield MD, Ridley A, Downward J (1997) Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89:457–467CrossRefPubMed Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, Waterfield MD, Ridley A, Downward J (1997) Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89:457–467CrossRefPubMed
8.
Zurück zum Zitat Urano, T, Emkey R, Feig LA (1996) Ral-GTPases mediate a distinct downstream signaling pathway from Ras that facilitates cellular transformation. EMBO J 15:810–816PubMed Urano, T, Emkey R, Feig LA (1996) Ral-GTPases mediate a distinct downstream signaling pathway from Ras that facilitates cellular transformation. EMBO J 15:810–816PubMed
9.
Zurück zum Zitat el-Fouly MH, Trosko JE, Chang CC, Warren ST (1989) Potential role of the human Ha-ras oncogene in the inhibition of gap junctional intercellular communication. Mol Carcinog 2:131–135PubMedCrossRef el-Fouly MH, Trosko JE, Chang CC, Warren ST (1989) Potential role of the human Ha-ras oncogene in the inhibition of gap junctional intercellular communication. Mol Carcinog 2:131–135PubMedCrossRef
10.
Zurück zum Zitat de Feijter AW, Ray JS, Weghorst CM, Klaunig JE, Goodman JI, Chang CC, Ruch RJ, Trosko JE (1990) Infection of rat liver epithelial cells with v-Ha-ras: correlation between oncogene expression, gap junctional communication, and tumorigenicity. Mol Carcinog 3:54–67PubMedCrossRef de Feijter AW, Ray JS, Weghorst CM, Klaunig JE, Goodman JI, Chang CC, Ruch RJ, Trosko JE (1990) Infection of rat liver epithelial cells with v-Ha-ras: correlation between oncogene expression, gap junctional communication, and tumorigenicity. Mol Carcinog 3:54–67PubMedCrossRef
11.
Zurück zum Zitat Tikoo A, Cutler H, Lo SH, Chen LB, Maruta H (1999) Treatment of Ras-induced cancers by the F-actin cappers Tensin and Chaetoglobosin K, in combination with the Caspase-1 inhibitor N1445. Cancer J Sci Am 5:293–300PubMed Tikoo A, Cutler H, Lo SH, Chen LB, Maruta H (1999) Treatment of Ras-induced cancers by the F-actin cappers Tensin and Chaetoglobosin K, in combination with the Caspase-1 inhibitor N1445. Cancer J Sci Am 5:293–300PubMed
12.
Zurück zum Zitat Hancock JF, Magee AI, Childs JE, Marshall CJ (1989) All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 57:1167–1177CrossRefPubMed Hancock JF, Magee AI, Childs JE, Marshall CJ (1989) All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 57:1167–1177CrossRefPubMed
13.
Zurück zum Zitat Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ (1992) Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 89:6403–6407PubMedCrossRef Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ (1992) Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 89:6403–6407PubMedCrossRef
14.
Zurück zum Zitat Ruch RJ, Sigler K (1994) Growth inhibition of rat liver epithelial tumor cells by monoterpenes does not involve ras plasma membrane association. Carcinogenesis 15:787–789PubMedCrossRef Ruch RJ, Sigler K (1994) Growth inhibition of rat liver epithelial tumor cells by monoterpenes does not involve ras plasma membrane association. Carcinogenesis 15:787–789PubMedCrossRef
15.
Zurück zum Zitat Haklai R, Weisz MG, Elad G, Paz A, Marciano D, Egozi Y, Ben-Baruch G, Kloog Y (1998) Dislodgment and accelerated degredation of Ras. Biochem 37:1306–1314CrossRef Haklai R, Weisz MG, Elad G, Paz A, Marciano D, Egozi Y, Ben-Baruch G, Kloog Y (1998) Dislodgment and accelerated degredation of Ras. Biochem 37:1306–1314CrossRef
16.
Zurück zum Zitat Reuveni H, Klein S, Levitzki A (2003) The inhibition of Ras farnesylation leads to an increase in p27Kip1 and G1 cell cycle arrest. Eur J Biochem 270:2759–2772CrossRefPubMed Reuveni H, Klein S, Levitzki A (2003) The inhibition of Ras farnesylation leads to an increase in p27Kip1 and G1 cell cycle arrest. Eur J Biochem 270:2759–2772CrossRefPubMed
17.
Zurück zum Zitat Cutler HG, Crumley F, Cox R (1980) Chaetoglobosin K: a new plant growth inhibitor and toxin from Diplodia macrospora. J Agric Food Chem 28:139–142CrossRefPubMed Cutler HG, Crumley F, Cox R (1980) Chaetoglobosin K: a new plant growth inhibitor and toxin from Diplodia macrospora. J Agric Food Chem 28:139–142CrossRefPubMed
18.
Zurück zum Zitat Matesic DF, Blommel ML, Sunman JA, Cutler SJ, Cutler HG (2001) Prevention of organochlorine-induced inhibition of gap junctional communication by chaetoglobosin K in astrocytes. Cell Biol Toxicol 17:395–408CrossRefPubMed Matesic DF, Blommel ML, Sunman JA, Cutler SJ, Cutler HG (2001) Prevention of organochlorine-induced inhibition of gap junctional communication by chaetoglobosin K in astrocytes. Cell Biol Toxicol 17:395–408CrossRefPubMed
19.
Zurück zum Zitat Schanne FA, Kane AB, Young EE, Farber JL (1979) Calcium dependence of toxic cell death: a final common pathway. Science 206:700–702PubMedCrossRef Schanne FA, Kane AB, Young EE, Farber JL (1979) Calcium dependence of toxic cell death: a final common pathway. Science 206:700–702PubMedCrossRef
20.
Zurück zum Zitat Matesic DF, Rupp HL, Bonney WJ, Ruch RJ, Trosko JE (1994) Changes in gap-junction permeability, phosphorylation, and number mediated by phorbol ester and non-phorbol-ester tumor promoters in rat liver epithelial cells. Mol Carcinog 10:226–236PubMedCrossRef Matesic DF, Rupp HL, Bonney WJ, Ruch RJ, Trosko JE (1994) Changes in gap-junction permeability, phosphorylation, and number mediated by phorbol ester and non-phorbol-ester tumor promoters in rat liver epithelial cells. Mol Carcinog 10:226–236PubMedCrossRef
21.
Zurück zum Zitat Laemmli NK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685CrossRefPubMed Laemmli NK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685CrossRefPubMed
22.
Zurück zum Zitat Goldman F, Hohl RJ, Crabtree J, Lewis-Tibesar K, Koretzky G (1996) Lovastatin inhibits T-cell antigen receptor signaling independent of its effects on ras. Blood 88:4611–4619PubMed Goldman F, Hohl RJ, Crabtree J, Lewis-Tibesar K, Koretzky G (1996) Lovastatin inhibits T-cell antigen receptor signaling independent of its effects on ras. Blood 88:4611–4619PubMed
23.
Zurück zum Zitat Ruch RJ, Madhukar BV, Trosko JE, Klaunig JE (1993) Reversal of ras-induced inhibition of gap-junctional intercellular communication, transformation, and tumorigenesis by lovastatin. Mol Carcinog 7:50–59PubMedCrossRef Ruch RJ, Madhukar BV, Trosko JE, Klaunig JE (1993) Reversal of ras-induced inhibition of gap-junctional intercellular communication, transformation, and tumorigenesis by lovastatin. Mol Carcinog 7:50–59PubMedCrossRef
24.
Zurück zum Zitat de Feijter AW, Matesic DF, Ruch RJ, Guan X, Chang CC, Trosko JE (1996) Localization and function of the connexin 43 gap-junction protein in normal and various oncogene-expressing rat liver epithelial cells. Mol Carcinog 16:203–212CrossRefPubMed de Feijter AW, Matesic DF, Ruch RJ, Guan X, Chang CC, Trosko JE (1996) Localization and function of the connexin 43 gap-junction protein in normal and various oncogene-expressing rat liver epithelial cells. Mol Carcinog 16:203–212CrossRefPubMed
25.
Zurück zum Zitat Na HK, Wilson MR, Kang KS, Chang CC, Grunberger D, Trosko JE (2000) Restoration of gap junctional intercellular communication by caffeic acid phenethyl ester (CAPE) in a ras-transformed rat liver epithelial cell line. Cancer Lett 157:31–38CrossRefPubMed Na HK, Wilson MR, Kang KS, Chang CC, Grunberger D, Trosko JE (2000) Restoration of gap junctional intercellular communication by caffeic acid phenethyl ester (CAPE) in a ras-transformed rat liver epithelial cell line. Cancer Lett 157:31–38CrossRefPubMed
26.
Zurück zum Zitat Sunman JA, Foster MS, Folse SL, May SW, Matesic DF (2004) Reversal of the transformed phenotype and inhibition of peptidylglycine alpha-monooxygenase in Ras-transformed cells by 4-phenyl-3-butenoic acid. Mol Carcinog 41:231–246CrossRefPubMed Sunman JA, Foster MS, Folse SL, May SW, Matesic DF (2004) Reversal of the transformed phenotype and inhibition of peptidylglycine alpha-monooxygenase in Ras-transformed cells by 4-phenyl-3-butenoic acid. Mol Carcinog 41:231–246CrossRefPubMed
27.
Zurück zum Zitat Na HK, Chang CC, Trosko JE (2003) Growth suppression of a tumorigenic rat liver cell line by the anticancer agent, ET-18-O-CH(3), is mediated by inhibition of cytokinesis. Cancer Chemother Pharmacol 51:209–215PubMed Na HK, Chang CC, Trosko JE (2003) Growth suppression of a tumorigenic rat liver cell line by the anticancer agent, ET-18-O-CH(3), is mediated by inhibition of cytokinesis. Cancer Chemother Pharmacol 51:209–215PubMed
28.
Zurück zum Zitat Musil LS, Goodenough DA (1991) Biochemical analysis of connexin43 intracellular transport, phosphorylation, and assembly into gap-junctional plaques. J Cell Biol 115:1357–1374CrossRefPubMed Musil LS, Goodenough DA (1991) Biochemical analysis of connexin43 intracellular transport, phosphorylation, and assembly into gap-junctional plaques. J Cell Biol 115:1357–1374CrossRefPubMed
29.
Zurück zum Zitat Cross DA, Alessi DR, Cohen P, Andjelkovic M, Hemmings BA (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785–788CrossRefPubMed Cross DA, Alessi DR, Cohen P, Andjelkovic M, Hemmings BA (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785–788CrossRefPubMed
30.
Zurück zum Zitat Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA (1996) Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15:6541–6551PubMed Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA (1996) Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15:6541–6551PubMed
31.
Zurück zum Zitat Maira SM, Galetic I, Brazil DP, Kaech S, Ingley E, Thelen M, Hemmings BA (2001) Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane. Science 294:374–379CrossRefPubMed Maira SM, Galetic I, Brazil DP, Kaech S, Ingley E, Thelen M, Hemmings BA (2001) Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane. Science 294:374–379CrossRefPubMed
32.
Zurück zum Zitat Vivanco I, Sawyers CI (2002) The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nature Rev 2:489–501CrossRef Vivanco I, Sawyers CI (2002) The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nature Rev 2:489–501CrossRef
33.
Zurück zum Zitat Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB, Gaffney PRJ, Reese CB, McCormick F, Tempst P, Coadwell J, Hawkins PT (1998) Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-triphosphate-dependent activation of protein kinase B. Science 279:710–714CrossRefPubMed Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB, Gaffney PRJ, Reese CB, McCormick F, Tempst P, Coadwell J, Hawkins PT (1998) Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-triphosphate-dependent activation of protein kinase B. Science 279:710–714CrossRefPubMed
34.
Zurück zum Zitat Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R, Kreisberg JI (2002) Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8:1168–1171PubMed Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R, Kreisberg JI (2002) Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8:1168–1171PubMed
35.
Zurück zum Zitat Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, Ghosh PM (2004) Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64:5232–5236CrossRefPubMed Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, Ghosh PM (2004) Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64:5232–5236CrossRefPubMed
36.
Zurück zum Zitat Hartwig, JH, Bokoch GM, Carpenter CL, Janmey PA, Taylor LA, Toker A, Stossel TP (1995) Thrombin receptor ligation and activated Rac uncap actin filament barbed ends through phosphoinositide synthesis in permeabilized human platelets. Cell 82:643–653CrossRefPubMed Hartwig, JH, Bokoch GM, Carpenter CL, Janmey PA, Taylor LA, Toker A, Stossel TP (1995) Thrombin receptor ligation and activated Rac uncap actin filament barbed ends through phosphoinositide synthesis in permeabilized human platelets. Cell 82:643–653CrossRefPubMed
37.
Zurück zum Zitat Yahara I, Harada F, Sekita S, Natori S, Yoshihira K (1982) Correlation between effects of 24 different cytochalasins on cellular structures and cellular events and those on actin in vitro. J Cell Biol 92:69–87CrossRefPubMed Yahara I, Harada F, Sekita S, Natori S, Yoshihira K (1982) Correlation between effects of 24 different cytochalasins on cellular structures and cellular events and those on actin in vitro. J Cell Biol 92:69–87CrossRefPubMed
Metadaten
Titel
Inhibition of cytokinesis and akt phosphorylation by chaetoglobosin K in ras-transformed epithelial cells
verfasst von
Diane F. Matesic
Kimberly N. Villio
Stacey L. Folse
Erin L. Garcia
Stephen J. Cutler
Horace G. Cutler
Publikationsdatum
01.06.2006
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 6/2006
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-005-0113-5

Weitere Artikel der Ausgabe 6/2006

Cancer Chemotherapy and Pharmacology 6/2006 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.